Article

Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene

Division of Experimental Hematology, Cincinnati Children's Hospital, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
EMBO Molecular Medicine (Impact Factor: 8.25). 07/2009; 1(4):236-48. DOI: 10.1002/emmm.200900027
Source: PubMed

ABSTRACT Understanding the biological pathways critical for common neurofibromatosis type 1 (NF1) peripheral nerve tumours is essential, as there is a lack of tumour biomarkers, prognostic factors and therapeutics. We used gene expression profiling to define transcriptional changes between primary normal Schwann cells (n = 10), NF1-derived primary benign neurofibroma Schwann cells (NFSCs) (n = 22), malignant peripheral nerve sheath tumour (MPNST) cell lines (n = 13), benign neurofibromas (NF) (n = 26) and MPNST (n = 6). Dermal and plexiform NFs were indistinguishable. A prominent theme in the analysis was aberrant differentiation. NFs repressed gene programs normally active in Schwann cell precursors and immature Schwann cells. MPNST signatures strongly differed; genes up-regulated in sarcomas were significantly enriched for genes activated in neural crest cells. We validated the differential expression of 82 genes including the neural crest transcription factor SOX9 and SOX9 predicted targets. SOX9 immunoreactivity was robust in NF and MPSNT tissue sections and targeting SOX9 - strongly expressed in NF1-related tumours - caused MPNST cell death. SOX9 is a biomarker of NF and MPNST, and possibly a therapeutic target in NF1.

Download full-text

Full-text

Available from: Meena Upadhyaya, Aug 21, 2015
1 Follower
 · 
198 Views
  • Source
    • "Gene expression data were derived from raw intensities using RMA (Irizarry et al. 2003). As the two data sets were from two different Affymetrix gene expression platforms, U95 (Henderson et al. 2005) and U133Plus2 (Miller et al. 2009), only the common probe sets (22218) between the two platforms were used in the feature analyses. DMRs and gene expression data were associated by Ensembl ID number. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Aberrant DNA methylation (DNAm) was first linked to cancer over 25 yr ago. Since then, many studies have associated hypermethylation of tumor suppressor genes and hypomethylation of oncogenes to the tumorigenic process. However, most of these studies have been limited to the analysis of promoters and CpG islands (CGIs). Recently, new technologies for whole-genome DNAm (methylome) analysis have been developed, enabling unbiased analysis of cancer methylomes. By using MeDIP-seq, we report a sequencing-based comparative methylome analysis of malignant peripheral nerve sheath tumors (MPNSTs), benign neurofibromas, and normal Schwann cells. Analysis of these methylomes revealed a complex landscape of DNAm alterations. In contrast to what has been reported for other tumor types, no significant global hypomethylation was observed in MPNSTs using methylome analysis by MeDIP-seq. However, a highly significant (P < 10(-100)) directional difference in DNAm was found in satellite repeats, suggesting these repeats to be the main target for hypomethylation in MPNSTs. Comparative analysis of the MPNST and Schwann cell methylomes identified 101,466 cancer-associated differentially methylated regions (cDMRs). Analysis showed these cDMRs to be significantly enriched for two satellite repeat types (SATR1 and ARLα) and suggests an association between aberrant DNAm of these sequences and transition from healthy cells to malignant disease. Significant enrichment of hypermethylated cDMRs in CGI shores (P < 10(-60)), non-CGI-associated promoters (P < 10(-4)) and hypomethylated cDMRs in SINE repeats (P < 10(-100)) was also identified. Integration of DNAm and gene expression data showed that the expression pattern of genes associated with CGI shore cDMRs was able to discriminate between disease phenotypes. This study establishes MeDIP-seq as an effective method to analyze cancer methylomes.
    Genome Research 02/2011; 21(4):515-24. DOI:10.1101/gr.109678.110 · 13.85 Impact Factor
  • Source
    • "In the article by Miller et al, 2009 (please see page 236 in this issue), the NF1 microarray consortium has addressed the question of the relationship between DNF, PNF and MPNSTs through analysis of the SC compartment. They isolated normal SCs, and SCs from DNFs and PNFs, and MPNSTs cell lines, comparing them using gene expression analysis. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In the war on cancer, a great deal of attention is being paid to knowing the 'enemy'. It is widely believed that by understanding the driving forces underlying cancer, researchers can develop better ways to target the disease. Currently, large-scale efforts have been under taken to completely characterize molecular changes in common human cancers (http://cancergenome.nih.gov/) (Collins & Barker, 2007). However, as more is learned about cancer, the debate increases on what exactly the enemy is: cells making up the bulk of the tumour, rare tumour stem cells that can regrow the tumour, tumour microenvironment, the subset of cancer cells with metastatic potential, etc. Studies of the cancers associated with Neurofibromatosis type 1 (NF1) are helping to define the relationship between many of these different cell types. It is still unclear how these different enemies are related to each other and how they interact to wage cancer's war on the patient. 'If you know the enemy and know yourself you need not fear the results of a hundred battles.' - Sun Tzu, The Art of War, c. 500 B.C.
    EMBO Molecular Medicine 07/2009; 1(4):198-200. DOI:10.1002/emmm.200900029 · 8.25 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Besprochen wird die für Diagnose, Prognose und Prädiktion des Therapieansprechens von Sarkomen wichtigste Gensignatur. Fast die Hälfte aller Sarkome weist eine einfache, spezifische Genläsion auf: rekurrente Translokationen (10–15% der Sarkome), spezifische aktivierende (GIST) bzw. inaktivierende (Rhabdoidtumoren) Mutationen, MDM2-Amplifikation in hoch- und entdifferenzierten Liposarkomen sowie in Intimasarkomen. Vor kurzem wurde eine Genexpressionssignatur veröffentlicht, die sich für die Prädiktion einer Metastasierung deutlich besser eignet als die histologische Graduierung. Sie besteht aus 67 Genen, die alle zu an der chromosomalen Integrität beteiligten Pfaden gehören, was für die besondere Rolle dieser Mechanismen bei der Entstehung von Metastasen spricht. Andererseits gibt es, mit Ausnahme von GIST mit KIT- and PDGFRA-Mutationen, bisher noch keine validierte prädiktive Gensignatur. This review reports the main gene signature specific for the diagnosis, prognosis or prediction of drug response in sarcomas. Almost half of sarcomas show a simple genetic lesion which is specific for the diagnosis: recurrent translocations in 10 to 15% of sarcomas, specific activating and inactivating mutations in GIST and rhabdoid tumor respectively, and MDM2 amplification in well-differentiated and dedifferentiated liposarcomas as well as in intimal sarcoma. A recent study reported a gene expression signature which is much better than histological grading for predicting metastasis outcome. This signature is composed of 67 genes all belonging to pathways involved in chromosome integrity suggesting an important role of these mechanisms in the development of metastases. On the other hand, and except for GIST with KIT and PDGFRA mutations, there is no validated predictive gene signature so far. SchlüsselwörterMolekularpathologie–Chromosomale Translokation–Fluoreszenz-in-situ-Hybridisierung–Mutation–Individualisierte Medizin KeywordsPathology, molecular–Chromosomal translocation–Fluorescent in situ hybridization–Mutation–Individualized medicine
    Der Pathologe 02/2011; 32(1):32-39. DOI:10.1007/s00292-010-1393-z · 0.64 Impact Factor
Show more